CareDx/$CDNA
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About CareDx
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre- and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company's commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically it generates the majority of its revenue from the United States. The company generates the majority of revenue from the Testing services.
- Ticker
- $CDNA
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 763
- Headquarters
- Brisbane, United States
- Website
- caredx.com
CareDx Metrics
BasicAdvanced
$4.5B
36.25
$2.41
-
-
Price and volume
Market cap
$4.5B
52-week high
$90.87
52-week low
$14.27
Average daily volume
1.5M
Financial strength
Current ratio
2.312
Quick ratio
2.146
Long term debt to equity
0.043
Total debt to equity
0.043
Profitability
EBITDA (TTM)
21.923
Gross margin (TTM)
70.97%
Net profit margin (TTM)
25.86%
Operating margin (TTM)
0.83%
Effective tax rate (TTM)
-3.55%
Revenue per employee (TTM)
$650,000
Management effectiveness
Return on assets (TTM)
0.48%
Return on equity (TTM)
33.04%
Valuation
Price to earnings (TTM)
36.254
Price to revenue (TTM)
9.044
Price to book
9.81
Price to tangible book (TTM)
22.26
Price to free cash flow (TTM)
75.279
Free cash flow yield (TTM)
1.33%
Free cash flow per share (TTM)
1.161
Growth
Revenue change (TTM)
38.94%
Earnings per share change (TTM)
98.44%
3-year revenue growth (CAGR)
18.74%
10-year revenue growth (CAGR)
29.88%
3-year earnings per share growth (CAGR)
12.56%
10-year earnings per share growth (CAGR)
1.72%
What the Analysts think about CareDx
Analyst ratings (Buy, Hold, Sell) for CareDx stock.
Analyst projections of the future price of CareDx stock.
Bulls say / Bears say
Q3 revenue rose 39% year on year and adjusted EBITDA doubled to $30 million. CareDx raised its 2026 revenue outlook to $520–530 million and adjusted EBITDA outlook to $90–100 million. (CareDx)
Medicare’s final coverage policy affirmed surveillance coverage for CareDx’s kidney, heart and lung tests. This reduces uncertainty over access to a key market for its transplant testing services. (CareDx)
An independent randomised trial found AlloSure-based monitoring cut kidney-transplant biopsies by 49%, with similar clinical outcomes. This evidence could support wider use of CareDx’s tests in transplant care. (CareDx)
Q3 testing revenue included $15 million from tests performed in earlier periods, up from $6 million a year earlier, while operating cash flow fell to $13 million from $37 million. This makes the strength and cash conversion of reported growth less clear. (CareDx)
NavDx adds integration and scaling risk: CareDx paid $160 million in cash for Naveris, with up to $100 million more contingent, while specialty-oncology revenue was $12 million in Q3. The company was still moving NavDx onto its billing platform. (CareDx)
AlloHeme and HistoMap are not yet commercial growth drivers: CareDx is targeting CLIA readiness by year-end 2026 and broader launches in 2027. Delays could defer the next contribution from its pipeline. (CareDx)
Data summarised monthly by Lightyear AI. Last updated on 30 Oct 2026.
CareDx Financial Performance
Revenues and expenses
CareDx Earnings Performance
Company profitability
Upcoming events
No upcoming events
CareDx News
AllArticlesVideos
Funds containing CareDx
Fund name | Fund size | $CDNA weighting |
|---|---|---|
iShares Healthcare Innovation£DRDR | $1.3B | 0.32% |
iShares Healthcare Innovation€2B78 | $1.2B | 0.32% |
iShares Healthcare Innovation$HEAL | $1.3B | 0.32% |
SPDR Russell 2000 US Small Cap£R2SC | $5.3B | 0.12% |
SPDR Russell 2000 US Small Cap€R2US | $5.3B | 0.12% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.